share_log

LifeMD to Report Second Quarter 2024 Financial Results on August 7

LifeMD to Report Second Quarter 2024 Financial Results on August 7

LifeMD將於8月7日公佈2024年第二季度財務報告
GlobeNewswire ·  07/30 08:00

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on August 7, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time.

納斯達克:LifeMD,Inc.(LFMD) announced(2024年7月30日),該公司是領先的虛擬初級保健服務提供商,將於2024年8月7日美國金融市場收盤後公佈2024年6月30日結束的前三個月和前六個月的財務業績,並將於東部時間下午4:30開始召開電話會議。

Conference Call & Webcast Details

電話會議和網絡研討會詳情

Date: Wednesday, August 7th
Time: 4:30 p.m. Eastern time
Toll-Free Dial-In: 1-800-245-3047
International Dial-In: 1-203-518-9765
Conference ID: LIFEMD
Live & Archived Webcast: Link
日期: 8月7日星期三
時間: 美國東部時間下午4點30分
免費撥號: 1-800-245-3047
國際撥入電話: 1-203-518-9765
會議ID: LIFEMD
現場及存檔網絡廣播: 連接

About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

關於LifeMD,Inc.
LifeMD是一家領先的虛擬初級保健服務提供商,爲超過200種疾病提供遠程醫療、實驗室和藥房服務,以及專業治療,包括初級保健、男性和女性健康、體重管理和激素療法。該公司利用垂直整合、專有數字保健平台、遍佈50個州的醫療團隊和總部位於美國的病人護理中心,增加高質量、可負擔的保健服務的接觸。欲了解更多信息,請訪問LifeMD.com。

Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com

投資者聯繫方式
LifeMD的致富金融官員Marc Benathen
marc@lifemd.com

Media Contact
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com

媒體聯繫人
首席營銷官Jessica Friedeman
press@lifemd.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論